Males and females differ in response to opioid agonist medications

Hendrée E. Jones, Heather Fitzgerald, Rolley E. Johnson

Research output: Contribution to journalArticlepeer-review


Few clinical trials include sex as a factor. This analysis explored within-sex differences in response to opioid agonist medications. Males and females randomly assigned to buprenorphine, LAAM, or methadone were compared on opioid use and retention in treatment. Females receiving buprenorphine had less objective drug use than females receiving methadone, while males receiving LAAM had less objective drug use than males receiving buprenorphine. Retention in treatment was longer for both sexes receiving methadone versus LAAM. Within-subject change results indicate that all three medications benefit both sexes. Clinical trials should be designed to examine the impact of sex on outcomes.

Original languageEnglish (US)
Pages (from-to)223-233
Number of pages11
JournalAmerican Journal on Addictions
Issue number3
StatePublished - May 2005

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Clinical Psychology
  • Psychiatry and Mental health


Dive into the research topics of 'Males and females differ in response to opioid agonist medications'. Together they form a unique fingerprint.

Cite this